IVGN: Gulf Coast Consortium Members to Use Invitrogen's Stealth siRNA Libraries in Screening Centers

Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced it has formed a strategic scientific relationship with researchers from Baylor College of Medicine and The University of Texas at Houston, part of the John S. Dunn Gulf Coast Consortium for Chemical Genomics (GCC-CG).

As part of the relationship, consortium members plan to use Invitrogen's broad gene expression and imaging portfolio to enable discovery of biomedically relevant aspects of gene and protein expression through advanced screening techniques. The screening centers will focus on many aspects of disease-related biology including diabetes, cancer and steroid hormone-related metabolic disorders.

Peter Davies, M.D., executive vice president of research at University of Texas Health Science Center, and director of GCC-CG, stated, "Invitrogen's siRNA screening technologies and their high content, high throughput assays will greatly assist us in a variety of research being conducted by GCC-CG researchers," a view echoed by Kathleen Matthews, chair of the Gulf Coast Consortia Oversight Committee.

Scientists at core facilities at Baylor College of Medicine and University of Texas Health Science Center will use their expertise in high content, high throughput image-based screening and quantitative gene expression, respectively, to maximize the biological content from these experiments. Initial experiments will use Invitrogen's human kinase, human nuclear receptor, and mouse nuclear receptor collections. The quantitative effects of the siRNA molecules on gene and protein expression will be assessed using Invitrogen's novel, highly sensitive SYBR GreenER(TM) real time qPCR technology, and image-based tools from its Molecular Probes(TM) portfolio.

"Invitrogen is committed to driving gene expression analysis techniques forward," said Amy Butler, Ph.D., vice president, gene expression profiling, at Invitrogen. "This broad collaboration with renowned research centers allows us to jointly make important contributions to new medical and drug development research."

Additional participating members of the GCC-CG are Rice University, University of Houston, The University of Texas M. D. Anderson Cancer Center, and The University of Texas Medical Branch at Galveston. Together the six institutions form a larger organization, the Gulf Coast Consortia.

"This partnership allows us to work with many key decision makers in the academic marketplace," said Lewis Vann, Ph.D, business development manager for Invitrogen's Consortium Program. "By combining resources and technologies we are maximizing the impact on consortium-based research."

"Access to Invitrogen's siRNA library and hardware/software resources for screens that reach down to the individual investigator laboratory is very efficient," said Michael A. Mancini, Ph.D., associate professor in the Department of Molecular and Cellular Biology at Baylor College of Medicine, and co-director of the GCC-CG.

About GCC
The Gulf Coast Consortia (GCC) brings together the strengths of its six member institutions to build interdisciplinary collaborative research teams and training programs in the biological sciences at their intersection with the computational, chemical, mathematical, and physical sciences. Comprised of six prominent and geographically proximate Gulf Coast institutions, Baylor College of Medicine, Rice University, University of Houston, University of Texas Health Science Center at Houston, University of Texas Medical Branch at Galveston and University of Texas M. D. Anderson Cancer Center, the GCC's goal is to provide a cutting edge collaborative training environment and research infrastructure, one beyond the capability of any single institution. The GCC's mission is to train the next generation of bioscientists and to enable scientists to ask and answer questions that cross scientific disciplines to address the challenging biological issues of our time and, ultimately, to apply the resulting expertise and knowledge to the treatment and prevention of disease.

IVGN: Invitrogen Partners with SciQuest to Provide Complete E-Procurement Solution to Customers

SciQuest, Inc., a leading provider of on-demand supplier management and procurement automation solutions, and Invitrogen Corporation Inc., a provider of essential life science technologies for disease research and drug discovery, today announced an e-procurement partnership. As part of this agreement, Invitrogen will offer SciQuest's software solution with its life sciences products and services to deliver a multi-vendor, e-procurement platform to targeted customers.

Invitrogen's partnership with SciQuest enables life science organizations the opportunity to benefit from Invitrogen's B2B services offering. Customers can learn from each other through Invitrogen's extensive experience in customer connectivity and best practices. The partnership will further seek opportunities to explore the integration into inventory management systems and scientific-based search tools, creating more efficiencies for the bench scientist and providing greater spend visibility and contract compliance for purchasing organizations.

"In working with life science clients eager to consolidate purchasing processes, we have found that combining expertise in e-procurement with knowledge of how bioscientists work allows us to provide significant value both to purchasing departments and to end users," said Steve Wiehe, president and CEO of SciQuest. "The combination of Invitrogen and SciQuest will allow both companies to offer this domain expertise and expand our customer base and market reach. This will also bolster SciQuest's continued support of commercial procurement initiatives."

"Our customers are under pressure to streamline their purchasing processes and often ask us to provide complete solutions," said Michael Stapleton, vice president, e-business marketing, at Invitrogen. "Invitrogen has developed multiple web-based programs that help meet this need, but by partnering with SciQuest, our ability to be the preferred one-stop shop increases exponentially, making us an even more valuable partner in the quest to provide essential technologies to life scientists."

In addition to the partnership, the two companies also announced the signing of numerous customers to the initiative: Sanger Institute, Exelixis, and Apoxis.

"Exelixis uses SAP and we had planned to implement connections to suppliers ourselves through SRM," said Delea Magana, purchasing manager at Exelixis. "We would not have known about the benefits of SciQuest without the introduction by Invitrogen. We look forward to getting our e-procurement solution implemented and shifting our procurement focus from transactional to strategic."

Nick Brown, procurement manager at Sanger Institute, added, "We eagerly look forward to the efficiency, customer service, control, and savings we expect to gain through our SciQuest implementation."

Invitrogen's offering of multi-vendor e-procurement technologies is the first of its kind within the life sciences industry. The partnership will allow clients to use SciQuest's software to purchase products from Invitrogen along with other vendors with a single purchase order instead of placing purchase orders with each different vendor. Such consolidation on a platform that offers supplier management, purchasing automation and materials management solutions allows clients to gain efficiency and control over their purchasing practices, driving savings in their organizations. For additional information on how to take advantage of this partnership email Invitrogen at ebusiness@invitrogen.com.

"Our research reveals that domain expertise is a strong criteria for clients when choosing an e-procurement provider," said Sudy Bharadwaj, vice president at the Aberdeen Group, a leading provider of fact-based research focused on the global technology-driven value chain. "The combined strength of Invitrogen with the technology foundation of SciQuest, brings to the market a powerful solution that delivers on this capability."

Representatives from SciQuest and Invitrogen will be highlighting the partnership during NextLevel 2007, taking place January 21-24 in San Diego, California. This invitation-only event is a forum for the exchange of best practices, networking with peers and exploring the future direction of electronic procurement and supplier relationship management. For more information, go to http://www.sciquest.com/nextlevel2007/

About SciQuest
SciQuest provides on-demand supplier enablement and procurement automation solutions that reduce operating costs, drive end-user adoption, bring more spend under management and increase visibility into organization-wide spending. Through SciQuest solutions, organizations gain immediate cost savings and rapid ROI.

Organizations can quickly enable a critical mass of suppliers through the SciQuest Supplier Network (SQSN) and leverage SciQuest Managed Services to fully manage catalog data and order delivery on an ongoing basis, significantly reducing the need for in-house IT and support resources. With an integrated supplier base, organizations can maximize on-contract spending and gain real-time visibility and reporting capabilities throughout the entire order process. In addition to a source-to-settle suite of e-procurement applications, SciQuest also offers supplier and order management modules that seamlessly integrate with existing ERP and enterprise financial systems, driving greater return from existing investments. For more information about SciQuest, please visit www.sciquest.com, or call 919.659.2100.

IVGN: Invitrogen to Partner with Wave Biotech, LLC to Supply Media-Filled Disposable Bioreactor Bags

Invitrogen Corporation, a provider of essential life science technologies for disease research and drug discovery, and Wave Biotech, LLC, a research-based company that develops and manufactures innovative process equipment for the pharmaceutical and biotechnology industries, today announced they entered into a partnership to supply media-filled disposable bioreactors. Under the agreement, Invitrogen Corporation will offer its GIBCO(R) brand cell culture media products to Wave Bioreactor(R) users in filled Cellbag(R) brand disposable bioreactor bags.

Invitrogen will offer both standard and custom media products in the standard O-series Cellbag(R) format. Disposable bioreactors and Cellbags(R) are easily customized to suit specific cell culture process needs for research, development or cGMP manufacturing operations. Media-filled Wave O-series Cellbags(R) are available for ordering through Invitrogen's e-commerce and custom product channels.

"This partnership creates a tremendously convenient solution for bioreactor users and will substantially reduce customer prep time and the inherent contamination risks and raw materials tracking issues associated with self-filling of bioreactor vessels," said Nicolas Barthelemy, Senior Vice President of Invitrogen's Cell Culture Systems division. "Invitrogen has already received many customer requests for filled bags, and is pleased to offer this increased convenience to our customers."

"The Wave Bioreactor system is differentiated from the rest of the bioreactor market by its commitment to the highest standards of quality and end-user convenience," said Daniella Kranjac, Vice President, Sales and Marketing at Wave Biotech. "Invitrogen's commitment to making its quality products readily accessible to Wave Bioreactor customers, and its knowledge of the specialized needs of research and bioproduction customers, were key factors in our selection of Invitrogen as our partner for this endeavor."

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company, which is celebrating 20 years of accelerating scientific discovery, provides essential life science technologies for disease research, drug discovery and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery, including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 scientists and other professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com

About Wave Biotech, LLC

Wave Biotech is a research-based company that develops and manufactures innovative process equipment for the pharmaceutical and biotechnology industries. The Company's focus is on developing disposable bioprocessing equipment. Key products, such as the Wave Bioreactor(R), Wave Mixer(R), FlexMixer(R) and Sterile Tube Fuser, feature disposable contact materials that eliminate cleaning and validation, thereby reducing costs in operations ranging from cell culture, media preparation, and buffer dissolution and thawing process intermediates to patient-specific cell therapy in hospitals. These unique, patented devices can be installed and commissioned rapidly, thereby drastically reducing the time-to-market for biological products. For additional information, visit www.wavebiotech.com